Specialty Pharmacy

Research could lead to the development of new cancer treatments.

Top news of the week in oncology drug development.

Viral minigenome modifies the virus and and produces particles that are no longer harmful to humans.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Reduction observed in stiffness, improvement of balance, and less fatigue reported as a result of taking part in the exercise program.

Since the Affordable Care Act, $20.8 billion has been saved on prescription drugs at an average of $1945 per beneficiary.

Cancer treatment advances are now moving to the clinic with great promise, just as precision therapy and immunotherapy are transforming cancer therapy itself.

HCV transmission model predicts significant long term effect of direct-acting antivirals.

Investigators seek to stop women's cancers before it starts to form.

Smoking puts HIV patients at greater risk of developing co-morbidities.

Nearly 40% of US employees have no access to paid sick leave.

Zepatier is priced considerably lower with similar efficacy to Harvoni and Sovaldi.

Trametinib and fluvastatin combination could block non-small cell lung cancer pathway activity.

New method penetrates tissue and kills the cancerous cells deep inside tumors.

Coffee appears to confer a number of protective effects against liver disease.

Nanoparticles found to stop disease progression in a model of chronic MS.

HIV viral reservoir widely considered the last barrier to a cure.

Uninsured rate decreased from 14.4% to 9.1% nationally in first 9 months of 2015.

The drug is the first biosimilar monoclonal antibody to be considered by the FDA.

Connecticut man achieves remission via Revlimid therapy while bolstered by the love of his wife and children.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the relationship between specialty pharmacies and accountable care organizations.

Researchers find the amplification and mutation of human epidermal growth factor receptor 2 should be treated separately.

Blincyto treats adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Compound aids in the delivery of copper to cells with damaged mitochondria, specifically in the spinal cord where amyotrophic lateral sclerosis treatment is needed.

Johns Hopkins will be the first hospital in the US to administer an HIV-positive kidney transplant and the first in the world to perform an HIV-positive liver transplant.

Patients with allergies and asthma have a deficiency in a protective protein called A20, which causes them to suffer more from allergens.

Treatment errors in HIV therapy injure thousands of patients annually.

More than 4 million consumers in HealthCare.gov states signed up for coverage this year.